Mastodawn

HAS France NMA Acceptability Framework: A Cross-Agency Evidence Planning Playbook.

https://www.mattheneus.com/editorial/fallback-canary-has-france-nma-acceptability-framework-evidence-planning-playbook-2026-03-27

#HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis

HAS France NMA Acceptability Framework: A Cross-Agency Evidence Planning Playbook

France's Haute Autorité de Santé (HAS) publishes explicit validity conditions for indirect treatment comparison (ITC) evidence that diverge from the binary RCT-only stance historically associated with German AMNOG. Understanding these conditions — and how they intersect with IQWiG and NICE methodology — is one of the highest-leverage planning activities a global evidence team can perform. This playbook maps the HAS acceptability framework for network meta-analysis (NMA) evidence, compares it…

AbangeLabs Editorial

AbangeLabs 7h ago

Bridging HAS and IQWiG Evidence Standards: A Cross-Border Network Meta-Analysis Planning Playbook.

https://www.mattheneus.com/editorial/fallback-canary-has-iqwig-cross-border-nma-evidence-planning-playbook-2026-03-26

#HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis

Bridging HAS and IQWiG Evidence Standards: A Cross-Border Network Meta-Analysis Planning Playbook

France and Germany impose distinct but reconcilable methodological requirements on indirect treatment comparison evidence. This playbook maps the divergences between HAS and IQWiG and provides an actionable architecture for building a single NMA and MAIC evidence package that satisfies both national agencies — reducing submission rework and eliminating cross-dossier inconsistency risk.

AbangeLabs Editorial

AbangeLabs 7h ago

MHRA's patient-information modernisation and device advice refresh set a new evidence-operations baseline.

https://www.mattheneus.com/editorial/mhra-improving-patient-information-device-regulatory-advice-evidence-operations-playbook-2026-03-19

#HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis

MHRA's patient-information modernisation and device advice refresh set a new evidence-operations baseline

MHRA updates published between 12 and 18 March 2026 indicate a tighter operational cadence for patient information and medical device regulatory advice. This playbook translates those signals into concrete evidence-governance actions for HTA and market access teams.

AbangeLabs Editorial

AbangeLabs 7h ago

EMA Management Board ePI roadmap turns product-information governance into an HTA evidence operations priority.

https://www.mattheneus.com/editorial/ema-management-board-epi-roadmap-evidence-operations-playbook-2026-03-14

#HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis

EMA Management Board ePI roadmap turns product-information governance into an HTA evidence operations priority

EMA Management Board updates on 13 March 2026 position electronic product information and implementation governance as immediate evidence-operations triggers. This playbook shows how decision teams can operationalise change detection, ITC assumption control, and auditable rerun logic.

AbangeLabs Editorial

AbangeLabs 13h ago

NMA outputs are now shaping HTA timelines before submission—not after. If your evidence plan starts late, your access strategy starts behind. https://www.mattheneus.com/editorial/hta-value-nma-projections-evidence #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs

How NMA Projections Reshape HTA Decision Timelines

Since the EU Health Technology Assessment Regulation (EU) 2021/2282 entered full application on 12 January 2025, network meta-analysis (NMA) outputs are being requested earlier in reimbursement workflows — including during joint scientific consultations before submission. This article examines what the shift means for evidence timing and how decision teams must adapt.

AbangeLabs Editorial

AbangeLabs 1d ago

Governance gets stronger when patient and consumer voice is formalized early in HTA. https://www.mattheneus.com/editorial/hta-consumer-panel-governance-playbook-singapore-ace-2026-03-29 #HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis

Consumer panel governance in HTA: what Singapore's new evidence signal means for submission teams

A newly published Singapore case study describes how a standing consumer panel shaped health technology assessment process and policy. The signal for evidence teams is operational: embed patient-priority inputs early, preserve assumption lineage through comparative and economic models, and document each governance decision transparently.

AbangeLabs Editorial

AbangeLabs 1d ago

Retractions can silently invalidate NMA assumptions days before dossier lock—if your evidence ops aren’t retraction-aware, you’re flying blind. New seven-day governance playbook: https://www.mattheneus.com/editorial/nma-retraction-ingestion-governance-playbook-2026-03-29 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs

NMA Retraction Signals Are Now an HTA Operations Risk: A Seven-Day Governance Playbook

A seven-day PubMed window shows concurrent NMA publication velocity and a newly indexed retraction note, highlighting a preventable governance gap for HTA teams. The operational answer is a retraction-aware evidence pipeline with versioned reruns and traceable propagation into economic evidence.

AbangeLabs Editorial

AbangeLabs 2d ago

CEE HTA bodies like Poland's AOTMiT face a dual challenge: aligning domestic benefit-assessment methodology with EU JCA evidence standards for ITC & NMA while preserving reimbursement integrity. A practical playbook for market-access teams.
https://www.mattheneus.com/editorial/aotmit-poland-itc-nma-eu-jca-evidence-standards-cee-market-access-playbook-2026-03-27
#HTA #NMA #EvidenceSynthesis #RegulatoryAffairs

AOTMiT and the EU JCA Era: How Central and Eastern European HTA Bodies Are Operationalising ITC and NMA Evidence Standards

As EU JCA joint clinical assessments move from pilot to routine in 2025–2026, Central and Eastern European HTA bodies face a dual challenge: satisfying the HTA Coordination Group's evidence expectations for indirect treatment comparisons (ITC) and network meta-analysis (NMA) while maintaining the integrity of domestic reimbursement processes.

AbangeLabs Editorial

AbangeLabs 2d ago

Publication bias is systematically under-tested in NMA dossiers — a scoping review of 22 critical appraisal instruments confirms no standardised decision rules exist. Comparison-adjusted funnel plots should be mandatory in HTA submissions: https://www.mattheneus.com/editorial/fallback-canary-publication-bias-nma-comparison-adjusted-funnel-plot-playbook-2026-03-28 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs

Publication Bias in Network Meta-Analysis: Why Comparison-Adjusted Funnel Plots Should Be Standard in HTA Submissions

A scoping review of 22 NMA critical appraisal instruments (Mondragon et al., J Clin Epidemiol, 2026) confirms that publication bias lacks standardised decision rules across all major tools. Comparison-adjusted funnel plots and selection model diagnostics are often absent from HTA submissions even as NICE and EU JCA assessors flag the omission. This playbook covers the three-layer protocol that should be standard in any NMA dossier.

AbangeLabs Editorial

ChrisM 3d ago

Tolles Interview von John Robb mit Joolz Denby, frühere aktive Förderin von New Model Army und noch aktuell die Erstellerin ihrer Albencover und T-Shirts, Tattookünstlerin, Autorin und Dichterin.

"All bands have tourdates on the back of their t-shirts. It's a bit of a nightmare. The print goes smaller and smaller and smaller."

https://www.youtube.com/watch?v=Yx_bhAwNH-U

#Joolz #JoolzDenby #NewModelArmy #NMA #postpunk #rock #alternativerock #interview #johnrobb #justinsullivan